Skip to content
OpenCapital
Get started

CorMedix CRMD Cash Provided by (Used in) Operating Activity, Including Discontinued Operation

Cash Provided by (Used in) Operating Activity, Including Discontinued Operation at other companies

Merit Medical Systems logo
Merit Medical SystemsMMSI
$40.68M+0.3%
Haemonetics logo
HaemoneticsHAE
$70.94M-39.1%
Baxter International logo
Baxter InternationalBAX
$213M+210%
Medline, Inc. logo
Medline, Inc. MDLN
$412M-39.6%
Pfizer logo
PfizerPFE
——
Solventum logo
SolventumSOLV
——

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×—
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%—
Net margin45.2%—
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%—
Debt / equity0×0.0×
Current ratio3×-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's cash provided by (used in) operating activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's cash provided by (used in) operating activity, including discontinued operation?
CorMedix (CRMD) reported cash provided by (used in) operating activity, including discontinued operation of $42.38M in Q1 2026.
How has CorMedix's cash provided by (used in) operating activity, including discontinued operation changed year-over-year?
CorMedix's cash provided by (used in) operating activity, including discontinued operation increased by 114.7% year-over-year, from $19.74M to $42.38M.
What is the long-term trend for CorMedix's cash provided by (used in) operating activity, including discontinued operation?
Over 4 years (2021 to 2025), CorMedix's cash provided by (used in) operating activity, including discontinued operation has grown at a 69.6% compound annual growth rate (CAGR), from -$21.16M to $175.05M.
What does cash provided by (used in) operating activity, including discontinued operation mean?
Measures the cash generated from the company's core business operations, excluding financing and investing activities. It reflects the ability of the company to convert revenue into actual cash flow after accounting for changes in working capital.